等待開盤 01-28 09:30:00 美东时间
-6.550
-3.56%
今日重点评级关注:HC Wainwright & Co.:维持Caribou Biosciences"买入"评级,目标价从3美元升至9美元;HC Wainwright & Co.:上调CervoMed评级至"买入",目标价从11美元升至25美元
2025-11-06 09:55
Dave Inc. shares are trading higher after the company reported Q3 earnings and ...
2025-11-04 20:34
Dave (NASDAQ:DAVE) raises FY2025 sales outlook from $505.000 million-$515.000 million to $544.000 million-$547.000 million vs $511.100 million estimate.
2025-11-04 20:31
Dave (NASDAQ:DAVE) reported quarterly earnings of $4.24 per share which beat the analyst consensus estimate of $1.82 by 132.97 percent. This is a 180.79 percent increase over earnings of $1.51 per share from the same
2025-11-04 20:29
今日重点评级关注:花旗:维持Caribou Biosciences"买入"评级,目标价从5美元升至8美元;HC Wainwright & Co.:上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入",目标价30美元
2025-11-04 10:31
Barrington Research analyst Gary Prestopino maintains Dave (NASDAQ:DAVE) with a Outperform and maintains $290 price target.
2025-11-03 21:03
Dave Inc. appoints Parker Barrile as Chief Product Officer, effective November 10. With experience from Prosper, LinkedIn, and as a partner at Norwest, Parker will lead Dave's product, design, and operations teams to expand financial offerings and enhance AI and credit capabilities. CEO Jason Wilk praises Parker's expertise in scaling consumer and financial products.
2025-10-29 12:00
Dave Inc.'s CEO, Jason Wilk, acknowledges his company's growing need to communicate better with a new breed of shareholders.
2025-10-23 05:06
Dave Inc. will host a conference call on November 4, 2025, at 8:30 a.m. Eastern time to discuss its Q3 2025 financial results. The call, including a Q&A session, will be accessible via phone or webcast. Details include toll-free and international dial-in numbers, as well as a webcast link. A replay and transcript will be available on the Company’s website. Dave, a leading U.S. neobank, provides affordable banking services. For investor inquiries,...
2025-10-21 12:38